Further Dissection of Cabozantinib in the Molecular Mechanism and Therapeutic Strategy of Flt3mut Aml: Exploring Mutational and Non-Mutational Resistance

Project title

深入檢視cabozantinib針對FLT3基因突變之血癌細胞的作用機制與運用策略：突變相關與非相關抗性的探討

Internal ID

MOST105-2320-B002-051-MY3

Principal Investigator

Start Date

August 1, 2017

End Date

July 31, 2018

Investigators

Partner Organizations

National Science and Technology Council